Know Cancer

or
forgot password

Fludarabine, Cyclophosphamide, Rituximab and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia


Phase 2
N/A
N/A
Open (Enrolling)
Both
Chronic Lymphocytic Leukemia

Thank you

Trial Information

Fludarabine, Cyclophosphamide, Rituximab and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia


During the study, you will have up to 6 "cycles" of treatment. A cycle is made up of
treatment with the study drugs for 3-4 days and then about 3-1/2 weeks (25 days) of no
treatment (about 4 weeks total). Treatment with the study drugs will be given for 4 days in
a row on the first cycle, and 3 days in a row on Cycles 2-6. On Day 1 of each cycle, you
will receive rituximab through a needle in a vein. On Cycle 1, since it is your first
exposure to rituximab, it must be given slowly, so it may take 6-8 hours to complete. On
the cycles after that, it can be given more rapidly, over 3-4 hours. Cyclophosphamide and
fludarabine will be given separately through a needle in a vein on Days 2-4 of Cycle 1 and
Days 1-3 of Cycles 2-6. Cyclophosphamide and fludarabine will each be given over 30
minutes. Bevacizumab will be given through a needle in a vein over 90 minutes on Day 3 of
Cycle 1. If it is well tolerated, the next dose of Bevacizumab will be given over 60
minutes on Day 2 of Cycle 2. If the Cycle 2 dose is well tolerated, the next doses of
Bevacizumab will be given over 30 minutes on Day 2 of Cycles 2-6. In addition to the study
drugs, you may also be given fluids by vein to help flush the kidneys, to help prevent
possible kidney damage. You may receive up to 6 cycles of treatment. Treatment will be
given on an outpatient basis. The injections for each daily treatment visit should take
less than 6 hours.

Up to 66 patients will take part in the study. All will be enrolled at M.D. Anderson.


Inclusion Criteria:



- Diagnosis of B-cell CLL

- Relapsed, fludarabine-sensitive (duration of response > 6 months as assessed by prior
treating physician) or fludarabine-naive patients

- Rai Stage III or IV, or Rai Stage I or II if determined to have disease progression
as evidenced by rapid doubling of peripheral lymphocyte count, progressive
lymphadenopathy, progressive splenomegaly, or B symptoms.

- Prestudy WHO Performance Status
- Signed, written IRB-approved informed consent.

- Men and women of reproductive potential must agree to follow accepted birth control
methods during treatment and for 3 months after completion of treatment.

- Acceptable liver function: Bilirubin (SGPT)
- Acceptable hematologic status: Platelet count >/= 50 x 10^9/L., ANC >/= 1 x 10^9/L.

- Acceptable renal function: Serum creatinine
Exclusion Criteria:

- Cancer radiotherapy, radioimmunotherapy, biological therapy, chemotherapy, or other
investigational therapy within 4 weeks prior to Study Day 1.

- Known infection with HIV, hepatitis B, or hepatitis C

- Transformation to aggressive B-cell malignancy (e.g., large B-cell lymphoma,
Richter's Syndrome, or prolymphocyte leukemia [PLL]).

- Patients with secondary malignancy requiring active treatment (except hormonal
therapy).

- Active uncontrolled bacterial, viral, or fungal infections.

- New York Heart Association Class II-IV cardiac disease or myocardial infarction
within the past 6 months prior to Study Day 1.

- Pregnant or currently breast-feeding.

- Current, recent (within 4 weeks of the first infusion of this study), or planned
participation in an experimental drug study other than a Genentech-sponsored
bevacizumab cancer study.

- Blood pressure of > 150/100 mmHg

- Unstable angina

- History of stroke within 6 months

- Clinically significant peripheral vascular disease

- Evidence of bleeding diathesis or coagulopathy

- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
prior to Day 1, anticipation of need for major surgical procedure during the course
of the study.

- Minor surgical procedures, fine needle aspirations or core biopsies within 7 days
prior to Day 1.

- Urine protein:creatinine ratio >/= 1.0 at screening.

- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal
abscess within 6 months prior to Day 1.

- Serious, non-healing wound, ulcer, or bone fracture.

Type of Study:

Interventional

Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Progression Free Survival (PFS) Rate

Outcome Time Frame:

2 Years

Safety Issue:

No

Principal Investigator

Susan O'Brien, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

M.D. Anderson Cancer Center

Authority:

United States: Institutional Review Board

Study ID:

MDACC-2005-0992

NCT ID:

NCT00448019

Start Date:

March 2007

Completion Date:

Related Keywords:

  • Chronic Lymphocytic Leukemia
  • Chronic Lymphocytic Leukemia
  • Fludarabine
  • Cyclophosphamide
  • Rituximab
  • Bevacizumab
  • CLL
  • Leukemia
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Leukemia, Lymphoid

Name

Location

UT MD Anderson Cancer CenterHouston, Texas  77030